Vireo Growth (VREOF) Total Liabilities (2020 - 2026)
Vireo Growth (VREOF) reported Total Liabilities of $634.7 million for Q1 2026, up 180.09% on a YoY basis from $226.6 million in Q1 2025, and up 24.5% sequentially from $509.8 million in Q4 2025.
Vireo Growth (VREOF) Total Liabilities (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Total Liabilities data on file, last reported at $634.7 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities rose 180.09% year-over-year to $634.7 million; the trailing twelve-month figure through Mar 2026 stood at $634.7 million (up 180.09% YoY), and the FY2025 full-year result was $509.8 million, up 128.3% from the prior year.
- Total Liabilities rose to $634.7 million in Q1 2026, from $509.8 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $634.7 million in Q1 2026 to a low of $131.6 million in Q1 2022.
- A 5-year average of $256.5 million and a median of $204.9 million in 2024 frame the typical range for Total Liabilities.
- Across the five-year window, Total Liabilities gained 6.16% in 2025 and soared 180.09% in 2026, its largest moves.
- Tracing VREOF's Total Liabilities over 5 years: stood at $155.7 million in 2022, then rose by 27.99% to $199.3 million in 2023, then rose by 12.04% to $223.3 million in 2024, then soared by 128.3% to $509.8 million in 2025, then rose by 24.5% to $634.7 million in 2026.
- Business Quant data shows VREOF's Total Liabilities at $634.7 million in Q1 2026, $509.8 million in Q4 2025, and $432.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.48 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 31.81 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.92 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 51.53 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 813.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 22.18 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.50 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.72 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 634.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 634.70 Mn |
| Dec 31, 2025 | 509.80 Mn |
| Sep 30, 2025 | 432.61 Mn |
| Jun 30, 2025 | 390.76 Mn |
| Mar 31, 2025 | 226.61 Mn |
| Dec 31, 2024 | 223.30 Mn |
| Sep 30, 2024 | 204.87 Mn |
| Jun 30, 2024 | 217.24 Mn |
| Mar 31, 2024 | 213.46 Mn |
| Dec 31, 2023 | 199.31 Mn |
| Sep 30, 2023 | 184.52 Mn |
| Jun 30, 2023 | 173.88 Mn |
| Mar 31, 2023 | 160.70 Mn |
| Dec 31, 2022 | 155.72 Mn |
| Sep 30, 2022 | 156.85 Mn |
| Jun 30, 2022 | 144.83 Mn |
| Mar 31, 2022 | 131.65 Mn |
| Dec 31, 2021 | 123.96 Mn |
| Sep 30, 2021 | 113.25 Mn |
| Jun 30, 2021 | 56.43 Mn |